Tapan M. Kadia

Hematology

210 Ashville Ave # 408
Cary, NC 27518

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 578 publications

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 27, 2026

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 23, 2026

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 02, 2026

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 11, 2026

Final results of a phase II study of the combination of azacitidine and ruxolitinib in patients with myelofibrosis.

Final results of a phase II study of the combination of azacitidine and ruxolitinib in patients with myelofibrosis.

Journal: Haematologica

Published: May 04, 2026

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Journal: Haematologica

Published: April 22, 2026

The Role of Advanced Molecular Diagnostics in Informing Targeted Therapies for AML.

The Role of Advanced Molecular Diagnostics in Informing Targeted Therapies for AML.

Journal: Human pathology

Published: April 20, 2026

Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.

Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.

Journal: Journal of hematology & oncology

Published: April 17, 2026

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.

Journal: Leukemia

Published: March 31, 2026

Short-chain fatty acid-producing microbes differentiate non-infectious and infectious neutropenic fever in leukemia.

Short-chain fatty acid-producing microbes differentiate non-infectious and infectious neutropenic fever in leukemia.

Journal: mSystems

Published: March 31, 2026

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.

Journal: Cancer

Published: March 30, 2026

Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes.

Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes.

Journal: Transplantation and cellular therapy

Published: March 26, 2026

Showing 1-12 of 578

Last Updated: 09/26/2026